Asset Management One Co. Ltd. Boosts Stake in Repligen Co. (NASDAQ:RGEN)

Asset Management One Co. Ltd. increased its position in Repligen Co. (NASDAQ:RGEN) by 9.7% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 21,425 shares of the biotechnology company’s stock after purchasing an additional 1,888 shares during the period. Asset Management One Co. Ltd.’s holdings in Repligen were worth $3,971,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in RGEN. Fortis Capital Advisors LLC purchased a new stake in Repligen during the fourth quarter valued at approximately $35,000. Park Place Capital Corp raised its position in Repligen by 90.2% during the third quarter. Park Place Capital Corp now owns 253 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 120 shares during the period. Signaturefd LLC raised its position in Repligen by 44.1% during the third quarter. Signaturefd LLC now owns 281 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 86 shares during the period. International Assets Investment Management LLC purchased a new stake in Repligen during the third quarter valued at approximately $51,000. Finally, UniSuper Management Pty Ltd purchased a new stake in Repligen during the second quarter valued at approximately $57,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Repligen news, VP Ralf Kuriyel sold 3,517 shares of the firm’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $193.73, for a total transaction of $681,348.41. Following the transaction, the vice president now directly owns 24,260 shares in the company, valued at approximately $4,699,889.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, VP Ralf Kuriyel sold 3,517 shares of Repligen stock in a transaction on Monday, March 11th. The stock was sold at an average price of $193.73, for a total value of $681,348.41. Following the transaction, the vice president now directly owns 24,260 shares in the company, valued at approximately $4,699,889.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Karen A. Dawes sold 1,000 shares of Repligen stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $193.35, for a total value of $193,350.00. Following the completion of the transaction, the director now owns 87,367 shares in the company, valued at $16,892,409.45. The disclosure for this sale can be found here. Insiders have sold 25,597 shares of company stock worth $5,039,532 in the last ninety days. 1.10% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on RGEN. JPMorgan Chase & Co. upped their price objective on Repligen from $170.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, December 20th. Stifel Nicolaus upped their price objective on Repligen from $165.00 to $207.00 and gave the company a “buy” rating in a research report on Thursday, February 22nd. Finally, KeyCorp upped their price objective on Repligen from $210.00 to $220.00 and gave the company an “overweight” rating in a research report on Thursday, February 15th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $196.70.

Repligen Trading Up 0.0 %

RGEN opened at $176.08 on Friday. The stock’s fifty day moving average is $192.65 and its two-hundred day moving average is $172.94. The company has a market capitalization of $9.83 billion, a P/E ratio of 244.56, a PEG ratio of 5.70 and a beta of 1.02. Repligen Co. has a 52 week low of $110.45 and a 52 week high of $211.13. The company has a quick ratio of 5.75, a current ratio of 7.02 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $0.33 EPS for the quarter, hitting the consensus estimate of $0.33. The company had revenue of $155.74 million for the quarter, compared to the consensus estimate of $155.38 million. Repligen had a return on equity of 5.00% and a net margin of 6.51%. Repligen’s quarterly revenue was down 16.6% on a year-over-year basis. During the same period last year, the business posted $0.68 EPS. Analysts forecast that Repligen Co. will post 1.46 earnings per share for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.